Esophageal squamous cell carcinoma (ESCC) is considered one of the most aggressive cancers with poor prognosis. The high molecular weight cytokeratin 34βE12 (CK34βE12) is recognized by the antibody, that is expressed in the cytoplasm of epithelial basal cells, and has been considered as a potential marker for prostate cancer, breast cancer, and basaloid carcinoma of the lung. However, there are no clinicopathological studies investigating CK34βE12 expression at the invasive front of ESCC. In this study, we examined 170 surgically resected cases of ESCC to clarify the clinicopathological significance of CK34βE12 expression. CK34βE12 expression was found in 85.3% (145/170) of ESCC cases and was significantly correlated with lymph node metastasis 
Esophageal squamous cell carcinoma (ESCC) exhibits geographic and ethnic variation throughout the world, with the highest incidences (> 50 per 100,000 population) recorded in northern Islamic Republic of Iran, various provinces of eastern China (Henan, Jiangsu, and Shanxi), and certain areas of Kazakhstan (2) . The prognosis for patients with ESCC is poor, and 5-year survival rates are about 10% (2) . In Japan, > 90% of all esophageal cancers are squamous cell carcinomas (6) , and the incidence of esophageal cancer is 20.0 per 100,000 population in males and 3.8 in females (13) , with the mortality rate of 15.4 per 100,000 population in males and 2.7 in females (15) . Despite advanced surgical strategies and postoperative management, ESCC is considered one of the most aggressive cancers with poor prognosis (1, 17) . One reason for the poor survival rate is that most patients present with advanced stages of the disease and lymph node metastasis, even in the early phase of esophageal wall invasion (8) . The lymph node metastasis is the crucial parameter for predicting survival (10, 25, 28) . The spread of cancer cells through the lymphatic system to regional lymph nodes is an important early event during tumor progression, and lymph node metastasis is an important factor in the staging of human cancers (21, 23) . Moreover, depth of invasion and presence of nodal or distant metastases are independent predictors of survival in ESCC patients (7, 9, 12) . Cytokeratin is one of the main structural proteins about the human epithelial cell, and divided into the two groups; acidic type (type 1) and a (neutral-to-) basic type (type 2). Moreover, cytokeratin is classified into the two groups about the molecular weight. The low molecular weight protein groups are 40 to 54 kD: CK7, 8, 17-20, and the high molecular weight protein groups are 48 to 67 kD: CK1-6, 9-16 (3). metastases; M1, distant metastases (22 (18) . In each patient, one representative histological specimen at the deepest invaded area of the esophageal cancer lesion was selected for immunohistochemistry. Paraffin sections measuring 4 μm in thickness were mounted on silane-coated glass slides. Immunohistochemical examination was performed on deparaffinized sections using the standard avidinbiotin-peroxidase complex (ABC) method with an automated immunostainer (Benchmark XT; Ventana Medical Systems, Tucson, AZ), using anti-human CK (clone 34βE12, mouse monoclonal, 1 : 50 dilution; DakoCytomation, Denmark). Heat-induced antigen retrieval was performed for each section.
Immunohistochemical evaluation. Two investigators (OM and KH) simultaneously assessed the immunostaining results without previous knowledge of the patients' clinicopathological details. Expression of CK34βE12 was evaluated at the invasive front of each tumor, given a score, and divided into following four groups: Score 0, no reactivity or faint reactivity in < 10% of tumor cells. Score 1+, faint or barely perceptible cytoplasmic reactivity in ≥ 10% of tumor cells. Score 2+, moderate and focal cytopasmic reactivity in ≥ 10% of tumor cells. Score 3+, throughout the cytoplasm is stained in ≥ 10% of tumor cells (Fig. 1) . Moreover, CK34βE12 is expressed in basal and spinous layers of normal stratified squamous epithelium (Fig. 1) .
Statistical analysis. Univariate statistical analysis was performed using the Pearson chi-square test or Fisher's exact test. The P values were two-sided, and P values of < 0.05 were considered statistically significant. All statistical analyses were performed using the SPSS Software (version 17.0; SPSS, Inc., Chicago, IL).
RESULTS

We detected positive CK34βE12 expression in
The high molecular weight cytokeratin 34βE12 (CK34βE12) is recognized by the antibody, that is identified as human cytokeratins 1, 5, 10, and 14 of Moll's catalogue (16) , is useful for the detection of epithelial basal cells, such as prostatic basal cells, and stratified squamous epithelium. CK34βE12 is expressed in the cytoplasm of basal cells, and has been used as a marker of the basal layer to distinguish benign from malignant processes in prostate cancer (5, 27) , breast cancer (14, 22) , and basaloid carcinomas of the lung (24) . Although a correlation between primary small cell carcinomas of the esophagus and CK34βE12 has been studied (11, 29) , no studies have investigated CK34βE12 expression at the invasive front of ESCC. In this study, we report the clinicopathological relationship of CK34βE12 in ESCC.
MATERIALS AND METHODS
Patient and tissue samples. All tissue specimens were obtained from surgically resected ESCCs at the Hirosaki University Hospital with informed consent from the patients. All patients underwent subtotal esophagectomy and dissection of lymph nodes. In this study, we examined 170 patients (153 males and 17 females) with a mean age of 64.5 years (range, 37-83 years). All patients were diagnosed with esophageal cancer, of which 53 patients had superficial cancers (mucosal or submucosa-invasive cancer) and 117 patients had advanced cancers (invades beyond the muscularis propria). Curative resection and regional lymph node dissection depended on the location of the primary tumors.
Histopathological and immunohistochemical examinations. For histological examination, ESCC tissue specimens were routinely fixed with formalin, embedded in paraffin, thin-sectioned, and stained with hematoxylin and eosin (H&E). The pathological stage of each case at the time of operation was defined according to the TNM classification (22) , and the lesions were graded histologically according to the Guidelines for Clinical and Pathologic Studies on Carcinoma of the Esophagus (26) . The TNM (tumor, node, metastasis) system with its four degrees of T, three degrees of N, and two degrees of M. T categories divided into following four groups: T1, tumor invades lamina propria or submucosa; T2, tumor invades into, but not beyond, the muscularis mucosa; T3, tumor invades the adventitia; T4, tumor invades adjacent structures. Moreover, M categories divided into following two groups: M0, no distant
The results of univariate analysis between lymph node metastasis and clinicopathological factors, including CK34βE12 expressions, are summarized in Table 1 . Lymph node metastasis was observed in 62.9% (107/170) cases. The gender and mean age were not significantly different (P = 0.368 and P = 0.381, respectively). ESCCs with lymph node metastasis exhibited significant differences in depth of tumor invasion, lymphatic invasion, infiltrative growth pattern (INF), and distant organ metastasis (pM) (P = 0.003, P = 0.001, P < 0.001, and P < 0.001, 85.3% (145/170) of the primary ESCCs examined. Typical immunohistochemical expression patterns of CK34βE12 are demonstrated in Fig. 1 . CK34βE12 expression was predominantly detected at the cell membrane and/or in the cytoplasm of tumor cells. In 97.9% (142/145) of CK34βE12-positive cases, expression was detected at the invasive front as well as in the majority of tumor cells, whereas only 3 cases did not show expression at the invasive front. These results suggested that majority of CK34βE12-positive cells are located at the tumor invasive front. sponded to well or moderately differentiated squamous cell carcinoma, whereas the CK34βE12-negative cases corresponded to poorly differentiated squamous cell carcinoma.
DISCUSSION
CK34βE12 has been studied as potential marker for urothelial cancer, breast cancer, and basaloid carcinoma of the lung (5, 14, 19, 24, 27) . It was shown that primary small cell carcinoma of the esophagus correlated with CK34βE12 expression (29) ; however, the relevance and expression of CK34βE12 in carcinoma cells have not yet been clarified in ordinary ESCC. This is the first study to demonstrate that CK34βE12 expression is a good indicator of lymph node metastasis in ESCC. respectively), but exhibited no significant differences in venous invasion and histological differentiation. The cases also revealed CK34βE12 expression (Score 2 and 3) to be a significant indicator of the incidence of lymph node metastasis (P = 0.034). The results of CK34βE12 expression (Score 2 and 3) in primary tumors are summarized in Table 2 . Positive CK34βE12 expression was identified in 85.3% (145/170) cases, with no significant differences in gender and mean age (P = 0.139 and P = 0.437, respectively). ESCCs with CK34βE12 expression exhibited significant differences in lymph node metastasis, depth of tumor invasion, and differentiation (P = 0.034, P = 0.042, and P = 0.013, respectively), but exhibited no significant difference in lymphatic/venous invasion, INF, and pM. There was a tendency that CK34βE12-positive cases corre- Our statistical analysis showed that ESCCs with lymph node metastasis were significantly different in depth of tumor invasion, lymphatic inversion, INF, and pM (P = 0.003, P = 0.001, P < 0.001, and P < 0.001, respectively). In addition, our study revealed CK34βE12-positive carcinoma cells to be a significant factor for lymph node metastasis (P = 0.034). In ESCC, lymph node metastasis is the crucial parameter for predicting survival (10, 25, 28) . Our study demonstrated that lymph node metastasis exhibited a varying correlation with clinicopathological factors and CK34βE12 expression in ESCC.
Other than lymph node metastasis, our results indicate that CK34βE12 expression in ESCC was significantly associated with depth of tumor invasion, and differentiation (P = 0.042, and P = 0.013, respectively), but showed no significant differences in lymphatic/venous invasion, INF, and pM. Depth of tumor invasion and presence of nodal or distant metastases have been shown to be independent predictors of survival in ESCC patients (7, 9, 12) , although histological differentiation is a poor prognostic factor. ESCC grading has traditionally been based on parameters of mitotic activity, nuclear atypia, and degree of squamous differentiation. However, according to the American Joint Committee on Cancer 2009 prognostic groupings (4), grading is a controversial method to determine prognosis (23) . Our present study demonstrated that CK34βE12 expression, as well as lymph node metastasis and depth of tumor invasion, can be considered as good prognostic indicators of ESCC. In the present study, CK34βE12 expression was detected at the invasive front and the majority of tu- mor cell membranes and cytoplasm. Histologically, the normal esophagus is lined by 500-to 800-μm thick mucosa, composed of non-keratinizing stratified squamous epithelium with subjacent lamina propria, which rests on the underlying muscularis mucosae. The stratified squamous epithelium has a basal layer and spinous layer. The basal layer and spinous layer in the stratified squamous epithelium normally express CK34βE12. When the cancer becomes advanced, cell proliferation occurs predominantly in the basal layer and the invasive front at the vertically deep areas, leading to a correlation between CK34βE12 expression and depth of tumor invasion. Interestingly, CK34βE12 is expressed in not only normal basal layer and spinous layer of stratified squamous epithelium, but also the cancer cells in ESCC.
In conclusion, we demonstrated that CK34βE12 expressed in the invasive areas of human ESCC is significantly correlated with lymph node metastasis, depth of tumor invasion, and differentiation. Lymph node metastasis and depth of tumor invasion are crucial parameters for predicting survival. Taken together, our findings suggest CK34βE12 to be a novel histological indicator of ESCC.
